Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy Planning, Computer-Assisted | 25 | 2024 | 1661 | 2.560 |
Why?
|
Protons | 16 | 2023 | 1116 | 1.840 |
Why?
|
Radiotherapy Dosage | 23 | 2024 | 2898 | 1.680 |
Why?
|
Monte Carlo Method | 9 | 2024 | 1258 | 1.510 |
Why?
|
Radiotherapy, Conformal | 5 | 2021 | 548 | 1.080 |
Why?
|
Radiotherapy, Intensity-Modulated | 7 | 2024 | 801 | 1.020 |
Why?
|
Phantoms, Imaging | 8 | 2024 | 2526 | 1.000 |
Why?
|
Linear Energy Transfer | 2 | 2024 | 152 | 0.870 |
Why?
|
Organs at Risk | 7 | 2024 | 359 | 0.770 |
Why?
|
Ependymoma | 1 | 2024 | 320 | 0.730 |
Why?
|
Titanium | 1 | 2023 | 485 | 0.690 |
Why?
|
Radiometry | 5 | 2024 | 813 | 0.520 |
Why?
|
Photons | 4 | 2017 | 589 | 0.500 |
Why?
|
Postoperative Care | 3 | 2018 | 1468 | 0.490 |
Why?
|
Mastectomy | 5 | 2021 | 1822 | 0.470 |
Why?
|
Radiography | 3 | 2013 | 6965 | 0.390 |
Why?
|
Radiotherapy, High-Energy | 1 | 2011 | 228 | 0.360 |
Why?
|
Chordoma | 3 | 2023 | 347 | 0.350 |
Why?
|
Semiconductors | 1 | 2011 | 100 | 0.350 |
Why?
|
Oxides | 1 | 2011 | 401 | 0.330 |
Why?
|
Breast Neoplasms | 8 | 2024 | 21012 | 0.310 |
Why?
|
Metals | 1 | 2011 | 719 | 0.270 |
Why?
|
Brain Neoplasms | 2 | 2024 | 9031 | 0.250 |
Why?
|
Silicon | 1 | 2024 | 142 | 0.220 |
Why?
|
Lung | 4 | 2021 | 10000 | 0.210 |
Why?
|
Scattering, Radiation | 3 | 2017 | 490 | 0.200 |
Why?
|
Calibration | 2 | 2022 | 818 | 0.190 |
Why?
|
Skull Base Neoplasms | 1 | 2023 | 270 | 0.160 |
Why?
|
Liver | 2 | 2022 | 7529 | 0.160 |
Why?
|
Radiation Dosage | 3 | 2018 | 1958 | 0.160 |
Why?
|
Brain Stem | 1 | 2024 | 858 | 0.160 |
Why?
|
Patient Positioning | 2 | 2018 | 326 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2018 | 1784 | 0.150 |
Why?
|
Spinal Neoplasms | 2 | 2014 | 716 | 0.150 |
Why?
|
Prostatic Neoplasms | 2 | 2019 | 11118 | 0.140 |
Why?
|
Microtechnology | 1 | 2017 | 70 | 0.140 |
Why?
|
Relative Biological Effectiveness | 5 | 2021 | 312 | 0.130 |
Why?
|
Uncertainty | 2 | 2019 | 754 | 0.130 |
Why?
|
Heart | 2 | 2021 | 4404 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 6 | 2023 | 20570 | 0.130 |
Why?
|
Tumor Burden | 3 | 2021 | 1893 | 0.130 |
Why?
|
Carotid Stenosis | 1 | 2023 | 860 | 0.130 |
Why?
|
Misonidazole | 1 | 2014 | 33 | 0.120 |
Why?
|
Algorithms | 6 | 2022 | 14031 | 0.120 |
Why?
|
Artifacts | 1 | 2023 | 1911 | 0.110 |
Why?
|
Breast Implants | 1 | 2018 | 411 | 0.110 |
Why?
|
Thoracic Wall | 1 | 2016 | 202 | 0.110 |
Why?
|
Head and Neck Neoplasms | 3 | 2024 | 2895 | 0.110 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2019 | 491 | 0.110 |
Why?
|
Humans | 36 | 2024 | 761504 | 0.100 |
Why?
|
Radiation Injuries | 2 | 2021 | 1189 | 0.100 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2013 | 136 | 0.100 |
Why?
|
Pituitary Neoplasms | 1 | 2021 | 1324 | 0.100 |
Why?
|
Cell Hypoxia | 1 | 2014 | 656 | 0.100 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1052 | 0.100 |
Why?
|
Fiducial Markers | 1 | 2013 | 132 | 0.100 |
Why?
|
Supratentorial Neoplasms | 1 | 2013 | 159 | 0.100 |
Why?
|
Mammaplasty | 1 | 2021 | 1239 | 0.090 |
Why?
|
Normal Distribution | 3 | 2019 | 272 | 0.090 |
Why?
|
X-Rays | 1 | 2011 | 307 | 0.090 |
Why?
|
Carbon | 1 | 2013 | 666 | 0.080 |
Why?
|
Gamma Rays | 1 | 2011 | 318 | 0.080 |
Why?
|
Liposarcoma, Myxoid | 1 | 2010 | 60 | 0.080 |
Why?
|
Technology Assessment, Biomedical | 1 | 2011 | 307 | 0.080 |
Why?
|
Cerebellar Neoplasms | 1 | 2013 | 586 | 0.080 |
Why?
|
Neoplasms | 2 | 2015 | 22170 | 0.070 |
Why?
|
Medulloblastoma | 1 | 2013 | 678 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2019 | 3466 | 0.070 |
Why?
|
Spine | 1 | 2014 | 1118 | 0.070 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2010 | 333 | 0.070 |
Why?
|
Radiotherapy | 1 | 2012 | 1499 | 0.060 |
Why?
|
Heart Ventricles | 1 | 2017 | 3807 | 0.060 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 2651 | 0.060 |
Why?
|
Lymphatic Irradiation | 1 | 2024 | 115 | 0.060 |
Why?
|
Computer Simulation | 3 | 2012 | 6240 | 0.050 |
Why?
|
Female | 13 | 2024 | 392644 | 0.050 |
Why?
|
Sarcoma | 1 | 2014 | 1801 | 0.050 |
Why?
|
Shoulder | 1 | 2024 | 300 | 0.050 |
Why?
|
Musculoskeletal System | 1 | 2024 | 188 | 0.050 |
Why?
|
Contrast Media | 1 | 2014 | 5311 | 0.050 |
Why?
|
Stroke | 1 | 2023 | 9757 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3530 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6485 | 0.040 |
Why?
|
Skull | 1 | 2023 | 818 | 0.040 |
Why?
|
Craniopharyngioma | 1 | 2021 | 277 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2014 | 13380 | 0.040 |
Why?
|
Nausea | 1 | 2021 | 679 | 0.040 |
Why?
|
Vomiting | 1 | 2021 | 651 | 0.040 |
Why?
|
Moyamoya Disease | 1 | 2021 | 265 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2021 | 64680 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 9000 | 0.030 |
Why?
|
Male | 8 | 2022 | 360804 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2014 | 9280 | 0.030 |
Why?
|
Models, Statistical | 3 | 2019 | 5079 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14666 | 0.030 |
Why?
|
Breast Implantation | 1 | 2018 | 223 | 0.030 |
Why?
|
Sacrococcygeal Region | 1 | 2014 | 53 | 0.030 |
Why?
|
Lymphocytes | 1 | 2022 | 2612 | 0.030 |
Why?
|
Pelvic Neoplasms | 1 | 2015 | 247 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1552 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2477 | 0.030 |
Why?
|
Vision Disorders | 1 | 2021 | 1088 | 0.030 |
Why?
|
Thoracic Neoplasms | 1 | 2015 | 267 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9469 | 0.030 |
Why?
|
Middle Aged | 6 | 2024 | 220895 | 0.030 |
Why?
|
Headache | 1 | 2021 | 1256 | 0.030 |
Why?
|
Sacrum | 1 | 2014 | 276 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36426 | 0.020 |
Why?
|
Chondrosarcoma | 1 | 2014 | 296 | 0.020 |
Why?
|
Subtraction Technique | 1 | 2014 | 512 | 0.020 |
Why?
|
Ions | 1 | 2012 | 256 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2012 | 251 | 0.020 |
Why?
|
Endocrine System Diseases | 1 | 2013 | 249 | 0.020 |
Why?
|
Cranial Irradiation | 1 | 2013 | 390 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2012 | 882 | 0.020 |
Why?
|
Technology, Radiologic | 1 | 2010 | 160 | 0.020 |
Why?
|
Thoracic Vertebrae | 1 | 2014 | 597 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2016 | 1302 | 0.020 |
Why?
|
Child | 3 | 2023 | 80153 | 0.020 |
Why?
|
Young Adult | 3 | 2021 | 59243 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 1 | 2015 | 916 | 0.020 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2013 | 781 | 0.020 |
Why?
|
Body Height | 1 | 2013 | 1570 | 0.020 |
Why?
|
Infant | 2 | 2021 | 36192 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2021 | 80636 | 0.020 |
Why?
|
Cell Communication | 1 | 2012 | 1657 | 0.020 |
Why?
|
Child, Preschool | 2 | 2021 | 42230 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2013 | 3514 | 0.010 |
Why?
|
Aged | 4 | 2020 | 169289 | 0.010 |
Why?
|
Lumbar Vertebrae | 1 | 2014 | 1879 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2012 | 20098 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2014 | 5247 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6484 | 0.010 |
Why?
|
Time Factors | 2 | 2018 | 39967 | 0.010 |
Why?
|
Cause of Death | 1 | 2013 | 3683 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5791 | 0.010 |
Why?
|
Pilot Projects | 1 | 2014 | 8631 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12725 | 0.010 |
Why?
|
Prospective Studies | 2 | 2014 | 54425 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 88319 | 0.010 |
Why?
|
Adult | 3 | 2019 | 221177 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 16981 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39106 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2014 | 58976 | 0.000 |
Why?
|
Brain | 1 | 2012 | 27112 | 0.000 |
Why?
|
Concepts
(145)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(42)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_